$CME

SHEPARD WILLIAM R purchased $3K of CME

SHEPARD WILLIAM R purchased 14 shares of CME GROUP INC. (CME) at $230.57 on 2026-06-25.

Original reporting
SEC EDGAR · SHEPARD WILLIAM R
Published Jun 29, 2026, 8:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CME
Neutral
high confidence
Mentioned
$CME
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMENeutralLow
01

Why it matters

The newest fact is the director’s open-market purchase details (14 shares at $230.57) and post-transaction holdings (3,621 shares).

02

Market read

Traders may note the insider buy, but the transaction is small and does not introduce new operational or financial information.

03

What to watch

No 10b5-1 plan is stated, but the filing lacks context on intent, timing constraints, or whether this is part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: after-hours/filing timestamp 2026-06-29; reflects 2026-06-25 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for CME Group Inc.

Company-level read

Ticker impact

$CMENeutralHigh confidence
Context

SEC Form 4 shows director SHEPARD WILLIAM R bought 14 shares of CME at $230.57 on 2026-06-25, totaling $3,301.30.

Expected impact

Likely minimal near-term impact; any effect is sentiment-only and small.

Evidence & confidence

The filing is a small, non-material insider buy (14 shares) with no 10b5-1 plan and no accompanying company news.

Market effects

None; this is company-specific insider transaction with no sector datapoint.

None indicated.

None indicated.

Counterpoint

A director purchase can be interpreted as confidence, but the disclosed size is too small to meaningfully change valuation expectations.

Key entities

  • CME Group Inc.

    Subject of the Form 4 insider transaction disclosure.

  • SHEPARD WILLIAM R

    Director who reported the open-market purchase.

Related articles

$TEAMMed

Stock Market Today: Dow Jones Futures Slip, S&P 500 Gains Ahead of July Jobs Report—Atlassian, Trade Desk

U.S. stock futures were mixed ahead of the July jobs report, with FactSet forecasting nonfarm payrolls up 97,500 and unemployment at 4.2%. 10-year Treasuries yielded 4.67% and FedWatch priced a 54.7% chance of a September hike. Atlassian (TEAM) rose on strong Q4 results; Trade Desk (TTD) fell on weak Q2 and soft guidance; Cloudflare (NET), Doximity (DOCS), and Sezzle (SEZL) also moved after earnings.

$NDAQMed

SEC sets Aug. 24 deadline in Nasdaq Bitcoin options review

The SEC ordered a full Commission review of Nasdaq PHLX’s proposed cash-settled Bitcoin index options (QBTC), after CME Group petitioned against a May 22 staff approval. The SEC set Aug. 24 as the deadline for written comments. The May approval remains stayed pending the Commission’s next order, with CFTC and OCC relief still required.

$CMEMed

CME Challenges Nasdaq Bitcoin Options Approval, Claims CFTC Has Exclusive Jurisdiction — BigGo Finance

CME Group challenged the SEC’s conditional approval of Nasdaq PHLX’s cash-settled bitcoin index options (ticker QBTC). CME says bitcoin is a commodity, so CFTC has exclusive jurisdiction, and the SEC exceeded its authority. The SEC initiated review and kept a stay. Comments are due Aug. 24. QBTC uses CME CF Bitcoin Real-Time Index and is cash-settled in USD.

$CMEMed

CME Says Bitcoin Index Options Fall Under CFTC, Challenges SEC Approval

CME Group challenged the SEC’s approval of Nasdaq PHLX cash-settled Bitcoin index options, arguing the product falls under CFTC jurisdiction because Bitcoin is a commodity, not a security. The SEC accepted CME’s petition July 29, stayed approval, and seeks comments through Aug. 24. Nasdaq plans to list under ticker QBTC, pending CFTC exemptive relief.